DK1121111T3 - Forbindelser til behandling af vægttab - Google Patents

Forbindelser til behandling af vægttab

Info

Publication number: DK1121111T3
Authority: DK; Denmark
Prior art keywords: patient; receptor antagonist; weight loss; inhibitor; administering
Prior art date: 1998-10-15

Application number

DK99947762.3T

Other languages

English (en)

Inventor

Andrew Coats

Stefan Anker

Original Assignee

Imp Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-15

Filing date

1999-10-15

Publication date

2010-05-31

1998-10-15 Priority claimed from GBGB9822459.5A external-priority patent/GB9822459D0/en

1998-10-15 Priority claimed from GBGB9822458.7A external-priority patent/GB9822458D0/en

1999-07-23 Priority claimed from GBGB9917181.1A external-priority patent/GB9917181D0/en

1999-10-15 Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd

2010-05-31 Application granted granted Critical

2010-05-31 Publication of DK1121111T3 publication Critical patent/DK1121111T3/da

Links

208000016261 weight loss Diseases 0.000 title abstract 3
230000004580 weight loss Effects 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 2
230000000694 effects Effects 0.000 abstract 4
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940044551 receptor antagonist Drugs 0.000 abstract 2
239000002464 receptor antagonist Substances 0.000 abstract 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 abstract 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
229940123329 Cathepsin B inhibitor Drugs 0.000 abstract 1
229940119334 Chymase inhibitor Drugs 0.000 abstract 1
229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 abstract 1
229940096915 Imidazoline receptor antagonist Drugs 0.000 abstract 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 abstract 1
229960002478 aldosterone Drugs 0.000 abstract 1
229940083712 aldosterone antagonist Drugs 0.000 abstract 1
239000002170 aldosterone antagonist Substances 0.000 abstract 1
239000002876 beta blocker Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003601 chymase inhibitor Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
239000003457 ganglion blocking agent Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229940127240 opiate Drugs 0.000 abstract 1
230000011514 reflex Effects 0.000 abstract 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 abstract 1
229960002646 scopolamine Drugs 0.000 abstract 1
210000002820 sympathetic nervous system Anatomy 0.000 abstract 1
229940075420 xanthine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Glass Compositions (AREA)
Signal Processing For Digital Recording And Reproducing (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
External Artificial Organs (AREA)

DK99947762.3T 1998-10-15 1999-10-15 Forbindelser til behandling af vægttab DK1121111T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9822459.5A GB9822459D0 (en)	1998-10-15	1998-10-15	Method of treatment
GBGB9822458.7A GB9822458D0 (en)	1998-10-15	1998-10-15	Methods of treatment
GBGB9917181.1A GB9917181D0 (en)	1999-07-23	1999-07-23	Methods of treatment
PCT/GB1999/003302 WO2000021509A2 (en)	1998-10-15	1999-10-15	Methods of treatment

Publications (1)

Publication Number	Publication Date
DK1121111T3 true DK1121111T3 (da)	2010-05-31

Family

ID=27269516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99947762.3T DK1121111T3 (da)	1998-10-15	1999-10-15	Forbindelser til behandling af vægttab

Country Status (9)

Country	Link
US (2)	US7417038B1 (da)
EP (1)	EP1121111B1 (da)
JP (1)	JP2002527378A (da)
AT (1)	ATE457169T1 (da)
CY (1)	CY1110282T1 (da)
DE (1)	DE69942009D1 (da)
DK (1)	DK1121111T3 (da)
PT (1)	PT1121111E (da)
WO (1)	WO2000021509A2 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69942009D1 (de) *	1998-10-15	2010-03-25	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
US20040122067A1 (en) *	2002-12-20	2004-06-24	Lin Zhao	Treatment of chronic heart failure
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
US7794987B2 (en)	2003-12-02	2010-09-14	Ucb Pharma Gmbh	Method for treating central neuropathic pain
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
EP1604655A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1784390A2 (en)	2004-08-13	2007-05-16	Amgen Inc.	Substituted benzofused heterocycles
US7528175B2 (en) *	2004-10-08	2009-05-05	Inverseon, Inc.	Method of treating airway diseases with beta-adrenergic inverse agonists
DK1814590T4 (da)	2004-11-01	2014-02-24	Amylin Pharmaceuticals Llc	Behandling af obesitet og beslægtede sygdomme.
CA2646131C (en) *	2005-03-21	2018-09-04	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (en)	2005-05-30	2016-03-30	Msd K.K.	Novel piperidine derivative
EP1916239A4 (en)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	PYRIDOLVERBINDUNG
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
US7875633B2 (en)	2005-08-24	2011-01-25	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
IE20050723A1 (en) *	2005-10-28	2007-05-30	Patrick T Prendergast	Anti-mineralocorticoid therapy of infection
EA019757B1 (ru)	2006-06-15	2014-06-30	ЮСиБи ФАРМА ГМБХ	Фармацевтическая композиция с синергетическим противосудорожным эффектом
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en)	2006-09-28	2009-10-21	Banyu Pharma Co Ltd	DIARYLKETIMINDERIVAT
GB0624282D0 (en) *	2006-12-05	2007-01-10	Cavalla David	Treatment of cachexia
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009220605A1 (en)	2008-03-06	2009-09-11	Msd K.K.	Alkylaminopyridine derivative
CA2717384A1 (en)	2008-03-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009257174A1 (en) *	2008-06-09	2009-12-17	Dimerix Bioscience Pty Ltd	Novel receptor hetero-dimers/-oligomers
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
RU2392933C2 (ru) *	2008-07-18	2010-06-27	Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН)	Средство, обладающее гиполипидемическими свойствами
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CA2732513C (en)	2008-08-01	2017-04-25	Arca Biopharma, Inc.	Methods and compositions involving (s)-bucindolol
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
GB0907350D0 (en)	2009-04-29	2009-06-10	Myotec Therapeutics Ltd	Methods
EP2523731B1 (en)	2010-01-14	2018-10-24	Novartis AG	Use of an adrenal hormone-modifying agent
MX2012009318A (es)	2010-02-10	2012-09-07	Novartis Ag	Metodos y compuestos para el crecimiento muscular.
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20130074808A (ko) *	2011-12-16	2013-07-05	한올바이오파마주식회사	스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
HRP20182041T1 (hr)	2013-03-14	2019-02-08	Actimed Therapeutics Ltd	Pripravci oksprenolola za liječenje raka
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
EP2832357A1 (en)	2013-07-29	2015-02-04	Charité - Universitätsmedizin Berlin	Selective AT2 receptor agonists for use in treatment of cachexia
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US11096908B2 (en)	2016-02-26	2021-08-24	Actimed Therapeutics Ltd	S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
US10799138B2 (en)	2018-04-05	2020-10-13	University Of Maryland, Baltimore	Method of administering sotalol IV/switch
US10512620B1 (en)	2018-08-14	2019-12-24	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en)	2018-08-14	2023-07-11	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en)	2018-08-14	2022-05-31	AltaThera Pharmaceuticals LLC	Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en)	2021-08-20	2023-03-21	AltaThera Pharmaceuticals LLC	Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en)	2021-08-20	2025-08-26	AltaThera Pharmaceuticals LLC	Anti-arrhythmic compositions and methods
EP3883930A1 (en)	2018-11-20	2021-09-29	Tes Pharma S.r.l.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10772869B1 (en)	2019-07-24	2020-09-15	ECI Pharmaceuticals, LLC	Pharmaceutical compositions including carvedilol and methods of using the same
GB2593902B (en)	2020-04-07	2022-04-13	Actimed Therapeutics Ltd	Salt of a pharmaceutical compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5541188A (en)	1987-09-15	1996-07-30	The Rowett Research Institute	Therapeutic applications of beta-adrenergic agonists
CA1337432C (en)	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US6545040B1 (en)	1988-03-23	2003-04-08	Janssen Pharmaceutica N.V.	Method of lowering the blood pressure
AU643487B2 (en) *	1989-11-21	1993-11-18	Sepracor, Inc.	Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders
EP0714663A3 (en)	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
NZ305528A (en)	1995-02-10	2001-05-25	G	Combination of angiotensin converting enzyme inhibitor and an aldosterone antagonist
JPH0971586A (ja)	1995-09-07	1997-03-18	Yamanouchi Pharmaceut Co Ltd	新規な二環性縮合イミダゾール誘導体
AUPO274596A0 (en)	1996-10-04	1996-10-31	Armstrong, Stuart Maxwell	Method for the treatment of neurological or neuropsychiatric disorders
GB9714675D0 (en)	1997-07-11	1997-09-17	Smithkline Beecham Plc	Novel composition
DE69942009D1 (de)	1998-10-15	2010-03-25	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
HUP0204262A2 (hu)	2000-01-31	2003-04-28	Pfizer Products Inc.	Benzogyűrűvel kondenzált heterociklusos csoportot tartalmazó nikotinamid-származékok, továbbá e vegyületeket tartalmazó, a PDE4 izozimek szelektív gátlására adható gyógyászati készítmények
WO2003065970A2 (en)	2001-02-20	2003-08-14	Royal College Of Surgeons Ie	Treatment of fibromyalgia and related fatigue syndromes using pindolol
WO2006030306A2 (en)	2004-09-17	2006-03-23	Neurocure Ltd	Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
US20060069086A1 (en)	2004-09-23	2006-03-30	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2646131C (en)	2005-03-21	2018-09-04	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
MX2008007790A (es)	2005-12-22	2009-03-04	Anaborex Inc	Composiciones y metodos para la prevencion y tratamiento de caquexia.
WO2007100775A2 (en)	2006-02-27	2007-09-07	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
CL2007003227A1 (es)	2006-11-09	2008-07-04	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
KR101546977B1 (ko)	2007-04-24	2015-08-24	아카시아 파마 리미티드	근육 손실의 치료에서의 약물 조합 및 그것의 용도
CA2753844A1 (en)	2008-03-05	2009-09-11	Vicus Therapeutics, Llc	Compositions and methods for mucositis and oncology therapies

1999
- 1999-10-15 DE DE69942009T patent/DE69942009D1/de not_active Expired - Lifetime
- 1999-10-15 PT PT99947762T patent/PT1121111E/pt unknown
- 1999-10-15 WO PCT/GB1999/003302 patent/WO2000021509A2/en not_active Ceased
- 1999-10-15 EP EP99947762A patent/EP1121111B1/en not_active Expired - Lifetime
- 1999-10-15 DK DK99947762.3T patent/DK1121111T3/da active
- 1999-10-15 US US09/807,558 patent/US7417038B1/en not_active Expired - Fee Related
- 1999-10-15 AT AT99947762T patent/ATE457169T1/de active
- 1999-10-15 JP JP2000575485A patent/JP2002527378A/ja active Pending
2008
- 2008-08-15 US US12/192,780 patent/US7829596B2/en not_active Expired - Fee Related
2010
- 2010-05-10 CY CY20101100408T patent/CY1110282T1/el unknown

Also Published As

Publication number	Publication date
US20090023639A1 (en)	2009-01-22
DE69942009D1 (de)	2010-03-25
US7829596B2 (en)	2010-11-09
PT1121111E (pt)	2010-05-17
ATE457169T1 (de)	2010-02-15
US7417038B1 (en)	2008-08-26
CY1110282T1 (el)	2015-01-14
WO2000021509A2 (en)	2000-04-20
WO2000021509A3 (en)	2000-11-09
EP1121111A2 (en)	2001-08-08
EP1121111B1 (en)	2010-02-10
JP2002527378A (ja)	2002-08-27

Publication	Publication Date	Title
CY1110282T1 (el)	2015-01-14	Ενωσεις για την αγωγη της απωλειας βαρους
ATE334985T1 (de)	2006-08-15	Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
IL149890A0 (en)	2002-11-10	Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
EP1059100A3 (en)	2003-12-03	Combinations of CRF antagonists and renin-angiotensin system inhibitors
UA49869C2 (uk)	2002-10-15	Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
WO2004017941A3 (en)	2004-04-22	Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2001001972A3 (en)	2001-12-06	SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2005047244A3 (en)	2006-12-21	Inhibition of fgfr3 and treatment of multiple myeloma
DE69720745D1 (de)	2003-05-15	Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
WO2003092606A3 (en)	2004-01-08	Cholinesterase inhibitors to prevent injuries caused by chemicals
ATE401913T1 (de)	2008-08-15	Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation
WO2000048446A3 (en)	2001-02-08	Use of antagonists of pg-e for the treatment of neuropathic pain
MY126321A (en)	2006-09-29	Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
IS4847A (is)	1998-09-15	Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
WO2001055176A3 (en)	2002-07-25	Methods for inhibiting smooth muscle cell proliferation
DK1503764T3 (da)	2010-05-10	5-HT4-receptor-antagonister til behandling af hjertesvigt
WO2000076457A3 (en)	2001-05-17	Il-8 receptor antagonists
MXPA02007454A (es)	2004-08-23	Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
WO2004011018A3 (en)	2004-05-06	Methods of identifying selective beta-1-adrenergic receptor antagonists
DK1121108T3 (da)	2003-07-21	Ny terapeutisk anvendelse af forbindelser med beta-3-agonistaktivitet
ECSP003564A (es)	2001-04-23	ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA
EP1095655A3 (en)	2003-03-26	NK-1 receptor antagonists and eletriptan for the treatment of migraine